

Registered number: 01723353
Charity number: 326374

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

UNAUDITED
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the Society, its Council members and advisers	1
Council members' report	2 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10 - 11
Notes to the financial statements	12 - 21

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE SOCIETY, ITS COUNCIL MEMBERS AND
ADVISERS
FOR THE YEAR ENDED 31 MARCH 2024**

Council members	Dr D Roberts, President Dr G D Poole Mrs C E George Dr I Sullivan Mr R C Haggas, Treasurer Miss J Staves Mrs R Braund Dr N Osaro Mr D Gaskin (appointed 30 January 2024)
Company registered number	01723353
Charity registered number	326374
Registered office	C/O Armstrong Watson 1st Floor One Strawberry Lane Newcastle Upon Tyne NE1 4BX
BBTS Executive Manager	David Noble
Accountants	Armstrong Watson LLP Chartered Accountants First Floor One Strawberry Lane Newcastle Upon Tyne NE1 4BX
Solicitors	Hay & Kilner LLP The Lumen St James' Boulevard Newcastle Helix Newcastle upon Tyne NE4 5BZ

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

COUNCIL MEMBERS' REPORT
FOR THE YEAR ENDED 31 MARCH 2024

The Council members present their annual report together with the financial statements of the The British Blood Transfusion Society for the year 1 April 2023 to 31 March 2024. The report serves the purposes of both a Council members' report and a directors' report under company law.

The Council members confirm that the report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Structure, governance and management

a. Governing document

The British Blood Transfusion Society was established in May 1983 as a company limited by guarantee governed by its Memorandum and Articles of Association (revised September 2011). It is registered as a charity with the Charity Commission. Every member undertakes to contribute such an amount not exceeding £1, as may be required in the event of the Society being wound up while he is a member or within one year after they cease to be a member.

b. Appointment of Council members

The Council members consist of officers, elected members and Past President or President Elect. Officers consist of the President of the Society who holds office for two years and the Secretary and Treasurer who hold office for three years. The President can remain as a Council member for a further year after retirement from the office of President. The Secretary and Treasurer are eligible for reappointment by Council, but neither can serve more than six consecutive years in office.

The elected Council members shall be those members of the Council who are not officers and shall each hold office for a period of three years; so far as possible they shall be made up of a mix of professional categories and be representative of the current membership; the period of office may be extended from time to time by the President for a year with a maximum of three extensions providing a maximum term of six years.

The Council members of the charitable company (excluding co-opted members) are its directors for the purposes of company law and trustees for the purposes of charity law. The elected Council members hold office for a period of three years.

Calls for nominations for officers and elected members of Council are made in the BBTS Bloodlines Newsletter and also on the Society's website. Nominees must be UK members and must have been a member of the Society for a minimum of two years. Nominations must be proposed and seconded by two Society members. Details of the nominees are then published on the ballot papers.

c. Induction and training of Council members

All new Council members are given an induction pack containing information, links and paperwork about the roles and responsibilities of trustees published by the Charity Commission. They also receive past Council meeting papers and dates of forthcoming Council meetings.

At the first meeting of the new Council, new members are introduced to individual Council members and specific areas of responsibility for new members are discussed and agreed. The Society's office then provides all the necessary background information and paperwork for new Council members' individual areas of responsibility.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

COUNCIL MEMBERS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

Structure, governance and management (continued)

d. Organisation

The Society is managed by the Council members, who are responsible for the strategic direction and overview of the work of the Society. The Council members must number at least eight and not more than fourteen, all of whom must be members of the Society. Three Council members (including at least one officer) are needed for a quorum.

There are committees and sub-committees of Council members that may co-opt members who are not members of the Council or Society. Co-opted members may not exceed three-quarters of the total number of such committees. These committees include the Executive Working Committee, the Scientific Meetings Administration Committee, the Communications Committee and the Professional Affairs & Education Committee.

The day to day operations of the charity are managed by the BBTS Executive Manager and a small team of staff from an office based in Manchester.

e. BBTS Enterprises Limited

The charity's wholly-owned subsidiary was incorporated in May 2003 and carries out trading activities for the charity. The subsidiary gift aids profits to the charity, subject to the retention of reserves for its own working capital requirements.

f. Risk management

The members of the Council are responsible for overseeing the risks faced by the Society. Within this process, detailed consideration of risks is delegated to the Executive Manager. Risks are identified, assessed and controls established throughout the year. Risks are held in a risk register. Council conducts ongoing reviews of the major risks to which the Society is exposed.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

COUNCIL MEMBERS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

Objectives, activities and performance

a. Objectives and activities

The main aim of the Society is to advance for the public benefit, the study of blood transfusion including immunohaematology and to promote research and development into all aspects of blood transfusion practice.

The objectives of the Society continue to be to:

- Provide education and training, including professional development
- Provide a forum for discussion and communication and facilitate the exchange of ideas between all groups through scientific meetings, special interest groups (SIGs) and the website
- Foster links with relevant national societies and organisations and ensure Society representation as appropriate
- Encourage research and development and disseminate information on new developments
- Contribute to the production of professional guidelines and promote best practice in all aspects of transfusion medicine
- Ensure recognition as the professional body for transfusion medicine by the government, health services and the public
- Contribute to the advancement of knowledge and services in developing countries

The Council sets itself annual objectives, in furtherance of the above main objectives of the Society. Each objective has a performance measure and responsibility is allocated to a Council member or Council sub-committee. Performance against the annual objectives is reviewed at Council meetings throughout the year and a progress report published in the Annual Review for members to view.

The Council confirm that they have been given the general guidance produced by the Charity Commission on public benefit including the guidance 'public benefit running a charity (PB2)'. The Council are confident that public benefit is achieved through the study of blood transfusion and development.

b. Achievements and performance

The Society's charitable activities focus on the study of blood transfusion and are undertaken to further its charitable purposes for the public benefit as described in the following paragraphs:

- The Society delivered its annual conference event in October 2023. The conference was held at the Harrogate HIC. The Society met its AGM obligations to members on time.
- The Society continued to protect its finances during the year and worked hard for members to ensure it can continue and expand on its works and activities in the years ahead.
- The education programmes continue to provide valuable education and training opportunities and set out transfusion best practice. 160 people took an examination with an overall 85% pass rate and 76 text books were separately purchased. Our VLE software was upgraded for the third consecutive year. The Moodle exam platform software, including online marking, performed well.
- The CPD scheme provides a specific framework for transfusion professionals. This year the Society had 522 members who were both registered and active on the scheme. CPD News continues to provide members relevant opportunities to learn and reflect. The Society continues to improve its online CPD tool for members to populate and submit returns electronically.
- Through engagement with all members at every step the Society has continued to work closely with its Equality, Diversity and Inclusion Committee establishing further updated Terms of Reference.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

COUNCIL MEMBERS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

Objectives, activities and performance (continued)

(continued)

- Successfully delivering six editions of the Society's Transfusion Medicine journal and four editions of its membership magazine Bloodlines.
- The Society has continued its representations as a professional body working towards the delivery of safe and effective transfusion practice.

During the year, Council achieved many of its major objectives including the improvement of our online course delivery and online exams, maintaining a strong Transfusion Medicine impact factor and gaining a respectable financial return from this journal.

The Society continues to work hard to rewrite and add to its CTP course content and now has two new Course Leads. We are planning to relaunch the course in 2025. We provided one educational webinar. The Transfusion Practitioners group has appointed a new Chair and Secretary as has the Components Special Interest Group. We continued to mitigate financial risk to the Society during this period whilst remaining almost entirely financially independent.

Membership of the Society has changed during the year as follows:

Number of members on 1 April 2023	1,490
Number of new members	191
Number of members who left	(175)
Number of members on 31 March 2024	1,506

Financial review

a. Results

The principal funding sources of the Society are from training income and membership subscriptions. Income from these sources is shown in note 5 to the financial statements.

The net movement in funds for the year was a deficit of £5,459 (2023: surplus £14,539), as shown in the statement of financial activities. There was a gift aid donation of £4,390 (2023: £nil) from the subsidiary this year, so the operational deficit was £9,849 (2023: surplus of £14,539). The group deficit for the year was £11,085 (2023: surplus £19,085).

b. Reserves policy

Council has established a policy whereby the unrestricted funds not committed, designated or invested in tangible fixed assets (the free reserves) held by the group should equate to at least £400,000. The reserves are needed to meet the ongoing working capital requirements of the group, to bridge any funding gaps during the development of new activities and to enable the group to continue its current activities in the event of a significant drop in income.

The free reserves of the charity as at 31 March 2024 were £398,652 (2023: £403,196) and those of the trading subsidiary add a further £88,980 (2023: £94,606), a total of £487,632 (2023: £497,802).

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

COUNCIL MEMBERS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

c. Investment powers and policy

Under the Memorandum and Articles of Association, the Society has the power to make investments as the Council members see fit.

Having regard to the Society's liquidity requirements and reserves policy, Council have, in recent years, operated a policy of keeping available funds in interest-bearing deposit accounts.

d. Going concern

After making appropriate enquiries, the Council members have a reasonable expectation that the Society has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

Plans for future periods

The Council has set itself a number of annual objectives for 2024/25, in furtherance of the main objectives of the Society. These objectives include the following:

- building on the strategies for membership expansion;
- a written update of its Transfusion Science Practice coursebook;
- relaunch of its Clinical Transfusion Practice course;
- to deliver more online webinars;
- continually enhance our online exams to improve delivery and marking;
- bring our SiGs and their goals closer to the day to day work of Council;
- continue to re-enforce our relationships with other professional bodies;
- launch a new membership grade for non-degree transfusion workers;
- introduce a new Early Career Professionals committee;
- create and launch an upgraded website and a BBTS mobile app;
- review the feasibility of awarding Chartered Scientist status;
- continue to ensure its finances are adequate following a withdrawal of funding;
- review alternative conference venues to protect our finances and reserves

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

COUNCIL MEMBERS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2024

Statement of Council members' responsibilities


The Council members (who are also the directors of the Society for the purposes of company law) are responsible for preparing the Council members' report including the Strategic report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Council members to prepare financial statements for each financial year. Under company law, the Council members must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Society and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Council members are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Society will continue in business.

The Council members are responsible for keeping adequate accounting records that are sufficient to show and explain the Society's transactions and disclose with reasonable accuracy at any time the financial position of the Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Council members and signed on their behalf by:


David J Roberts

David J Roberts (Oct 9, 2024 08:59 GMT+1)

Dr D Roberts

Date: 12 September 2024

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2024

Independent examiner's report to the Council members of The British Blood Transfusion Society ('the Society')

I report to the charity Council members on my examination of the accounts of the Society for the year ended 31 March 2024.

Responsibilities and basis of report

As the Council members of the Society (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Society are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Society's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Society as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Society's Council members, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Society's Council members those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Society and the Society's Council members as a body, for my work or for this report.

Signed:

Dated: 8 October 2024

D R Gold BA FCA

Independent Examiner

Armstrong Watson LLP
One Strawberry Lane
Newcastle upon Tyne
NE1 4BX

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2024**

	Note	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Income from:					
Donations	3	4,568	24,000	28,568	38,000
Investments	4	13,337	-	13,337	4,716
Charitable activities	5	257,776	-	257,776	262,240
Total income		275,681	24,000	299,681	304,956
Expenditure on:					
Charitable activities		281,140	24,000	305,140	290,417
Total expenditure		281,140	24,000	305,140	290,417
Net (expenditure) income and movement in funds		(5,459)	-	(5,459)	14,539
Reconciliation of funds:					
Total funds brought forward		450,122	-	450,122	435,583
Net movement in funds		(5,459)	-	(5,459)	14,539
Total funds carried forward		444,663	-	444,663	450,122

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 12 to 21 form part of these financial statements.

THE BRITISH BLOOD TRANSFUSION SOCIETY

(A company limited by guarantee)

REGISTERED NUMBER: 01723353

BALANCE SHEET
AS AT 31 MARCH 2024

	Note	2024 £	2023 £
Fixed assets			
Intangible assets	10	44,956	44,956
Tangible assets	11	1,054	1,969
Investments	12	1	1
		<u>46,011</u>	<u>46,926</u>
Current assets			
Debtors	13	137,115	100,972
Cash at bank and in hand		391,329	478,541
		<u>528,444</u>	<u>579,513</u>
Creditors: amounts falling due within one year	14	(123,460)	(169,985)
Net current assets		<u>404,984</u>	<u>409,528</u>
Total assets less current liabilities		<u>450,995</u>	<u>456,454</u>
Capital grant		(6,332)	(6,332)
Net assets		<u>444,663</u>	<u>450,122</u>
Total net assets		<u><u>444,663</u></u>	<u><u>450,122</u></u>

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)
REGISTERED NUMBER: 01723353

BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2024

	Note	2024 £	2023 £
Charity funds			
Restricted funds	15	-	-
Unrestricted funds	15	444,663	450,122
Total funds		444,663	450,122

The Society was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Council members acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Council members and signed on their behalf by:

David J Roberts
David J Roberts (Oct 9, 2024 08:59 GMT+1)

Dr D Roberts

Mr R C Haggas

Date: 12 September 2024

The notes on pages 12 to 21 form part of these financial statements.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1. General information

The Society is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is limited to £1.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared in sterling which is the functional and presentation currency of the charity.

The British Blood Transfusion Society meets the definition of a public benefit entity under FRS 102.

Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is included in the statement of financial activities when the charity is entitled to the income and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income:

Donations are received by way of grants and donations and are included in full in the Statement of financial activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income from charitable activities includes income from membership subscriptions and training and is recognised in the period in which the Society is entitled to receipt. Deferred income represents amounts received for future periods and is released to the statement of financial activities for the period for which it has been released.

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity.

Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Society's objectives, as well as any associated support costs.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.3 Expenditure (continued)

All expenditure is inclusive of irrecoverable VAT.

2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Society; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.5 Intangible assets and amortisation

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its expected useful life.

The estimated useful lives are as follows:

Website costs	-	5 years
---------------	---	---------

2.6 Tangible fixed assets and depreciation

Tangible fixed assets are included in the financial statements at their historical cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

Fixtures and fittings	-	20% On straight line basis
Computer equipment	-	25% On straight line basis

2.7 Investments

The investment in the subsidiary undertaking is included in the financial statements at cost. The financial statements for the Society include only the individual parent charity and are not consolidated to include the trading subsidiary. The parent charity is not required to prepare consolidated financial statements under section 399 of the Companies Act 2006 and is exempted by section 139(2) of the Charities Act 2011 from the requirement to prepare group accounts.

2.8 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.9 Cash at bank and in hand

Cash at bank includes a current account and an instant access COIF Charities Deposit Fund account.

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2. Accounting policies (continued)

2.10 Liabilities

Liabilities and provisions are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Society anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.11 Financial instruments

The Society only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

2.12 Fund structure

General funds are unrestricted funds which are available for use at the discretion of the Council members in furtherance of the general objectives of the Society and which have not been designated for other purposes. The general fund is credited with subscriptions received from members and income from training courses and associated income. It is charged with the charitable expenditure and governance costs of the Society.

Designated funds comprise unrestricted funds that have been set aside by the Council members for particular purposes. The aim and use of any designated fund is set out in the notes to the financial statements.

Grants obtained for specific purposes are recognised in the financial statements as restricted funds.

Investment income, gains and losses are allocated to the appropriate fund.

2.13 Judgements and key sources of estimation uncertainty

In applying the Society's accounting policies, the Council members are required to make judgements, estimates and assumptions in determining the carrying amounts of assets and liabilities. The Council members' judgements, estimates and assumptions are based on the best and most reliable evidence available at the time when the decisions are made, and are based on historical experience and other factors that are considered to be applicable.

Due to the inherent subjectivity involved in making such judgements, estimates and assumptions, the actual results and outcomes may differ. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

3. Income from donations

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Donations	4,568	-	4,568
Grants	-	24,000	24,000
	<u>4,568</u>	<u>24,000</u>	<u>28,568</u>

	<i>Restricted funds 2023 £</i>	<i>Total funds 2023 £</i>
Grants	<u>38,000</u>	<u>38,000</u>

4. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Bank interest	13,337	13,337	4,716
	<u>13,337</u>	<u>13,337</u>	<u>4,716</u>

5. Charitable activities

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Membership subscriptions	116,532	116,532	115,109
Training	141,244	141,244	147,131
	<u>257,776</u>	<u>257,776</u>	<u>262,240</u>

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

6. Independent examiner's remuneration

	2024	2023
	£	£
Fees payable to the Society's independent examiner for the independent examination of the Society's annual accounts	1,228	1,170
Fees payable to the Society's independent examiner in respect of: All other services not included above	8,833	7,744
	<u>8,833</u>	<u>7,744</u>

7. Total resources expended

	Charitable activities	Governance costs	Total 2024	<i>Total 2023</i>
	£	£	£	£
Direct costs				
Meetings and conferences	-	-	-	1,115
Publicity and publications	7,355	-	7,355	6,254
Bursaries and awards	932	-	932	97
Educational programme	83,392	-	83,392	81,624
Modernising Scientific Careers	23,562	-	23,562	22,498
Allocated support costs				
Staff costs	110,690	14,274	124,964	110,606
Office costs	38,388	16,182	54,570	58,179
Depreciation	641	275	916	1,130
Accountancy fees	4,326	4,326	8,652	8,287
Legal and other professional fees	558	239	797	627
	<u>269,844</u>	<u>35,296</u>	<u>305,140</u>	<u>290,417</u>

8. Staff costs and numbers

	2024	2023
	£	£
Wages and salaries	158,991	139,638
National insurance costs	10,724	9,017
Pension costs	<u>8,797</u>	<u>6,132</u>
	<u>178,512</u>	<u>154,787</u>

Average number of employees in the year (all management and administrative)	<u>5</u>	<u>5</u>
--	-----------------	----------

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

9. Council members' remuneration and expenses

During the year, no Council members received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 March 2024, expenses totalling £761 were reimbursed or paid directly to 4 Council members (2023 - £164 to 1 Council member).

10. Intangible assets

	Website £
Cost	
At 1 April 2023	44,956
At 31 March 2024	44,956
Net book value	
At 31 March 2024	44,956
At 31 March 2023	44,956

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

11. Tangible fixed assets

	Fixtures and fittings £	Computer equipment £	Total £
Cost or valuation			
At 1 April 2023	9,122	6,930	16,052
At 31 March 2024	<u>9,122</u>	<u>6,930</u>	<u>16,052</u>
Depreciation			
At 1 April 2023	9,091	4,992	14,083
Charge for the year	31	884	915
At 31 March 2024	<u>9,122</u>	<u>5,876</u>	<u>14,998</u>
Net book value			
At 31 March 2024	<u>-</u>	<u>1,054</u>	<u>1,054</u>
<i>At 31 March 2023</i>	<u>31</u>	<u>1,938</u>	<u>1,969</u>

12. Fixed asset investments

	Investments in subsidiary companies £
Cost or valuation	
At 1 April 2023	1
At 31 March 2024	<u>1</u>
Net book value	
At 31 March 2024	<u>1</u>
<i>At 31 March 2023</i>	<u>1</u>

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

13. Debtors

	2024 £	2023 £
Due within one year		
Trade debtors	42,550	20,490
Amounts due from subsidiary undertakings	87,073	66,989
Prepayments and accrued income	7,492	13,493
	<u>137,115</u>	<u>100,972</u>

14. Creditors: Amounts falling due within one year

	2024 £	2023 £
Trade creditors	3,624	11,181
Other taxation and social security	3,650	4,829
Other creditors	1,441	1,309
Accruals and deferred income	114,745	152,666
	<u>123,460</u>	<u>169,985</u>
	2024 £	2023 £
Deferred income at 1 April 2023	136,430	134,876
Resources deferred during the year	104,263	136,430
Amounts released from previous periods	(136,430)	(134,876)
	<u>104,263</u>	<u>136,430</u>

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

15. Statement of funds

Statement of funds - current year

	Balance at 1 April 2023 £	Income £	Expenditure £	Balance at 31 March 2024 £
Unrestricted funds				
General Fund	450,122	275,681	(281,140)	444,663
Restricted funds				
Educational Programme Fund	-	24,000	(24,000)	-
Total of funds	450,122	299,681	(305,140)	444,663

16. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Total funds 2024 £
Tangible fixed assets	1,054	1,054
Intangible fixed assets	44,956	44,956
Fixed asset investments	1	1
Current assets	528,444	528,444
Creditors due within one year	(123,460)	(123,460)
Capital grant	(6,332)	(6,332)
Total	444,663	444,663

THE BRITISH BLOOD TRANSFUSION SOCIETY
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024**

16. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior period

	<i>Unrestricted funds 2023 £</i>	<i>Total funds 2023 £</i>
Tangible fixed assets	1,969	1,969
Intangible fixed assets	44,956	44,956
Fixed asset investments	1	1
Current assets	579,513	579,513
Creditors due within one year	(169,985)	(169,985)
Capital grant	(6,332)	(6,332)
Total	<u>450,122</u>	<u>450,122</u>

17. Principal subsidiaries

The following was a subsidiary undertaking of the Society:

Name	Company number	Principal place of business	Class of shares
BBTS Enterprises Limited	4775642	England	Ordinary

Holding

100%

The financial results of the subsidiary for the year were:

Name	Income £	Expenditure £	(Deficit) for the year £
BBTS Enterprises Limited	380,827	382,063	(1,236)
Net assets £			

98,980